UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 13, 2007

 

 

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

128 Sidney Street, Cambridge, MA 02139

(Address of principal executive offices)   (Zip Code)

 

 

Registrant’s telephone number, including area code: (617) 995-2500

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

ITEM 5.02 — DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

 

(a) — (c)  Not applicable.

 

(d)  On November 13, 2007, the Board of Directors of ImmunoGen, Inc. (the “Company”) voted to expand the size of the Board from six to seven members, and elected Richard J. Wallace to fill the newly-created vacancy.  Mr. Wallace will also serve as a member of the Compensation Committee of the Board of Directors.

 

Mr. Wallace has more than thirty years of experience in strategic product development and commercialization gained at leading healthcare companies and is currently a Senior Vice President of Research and Development at GlaxoSmithKline.  Over his fifteen-year career at GlaxoSmithKline and its predecessors, Glaxo Wellcome and Glaxo, Mr. Wallace has held positions of increasing responsibility including Vice President, Sales and Marketing for oncology products at Glaxo Wellcome, Vice President, Therapeutic Development and Product Strategy at Glaxo Wellcome, and Vice President, Clinical Development and Product Strategy at GlaxoSmithKline.  Before joining Glaxo Canada in 1992, Mr. Wallace held commercialization and/or strategic development-related positions at Unilever, Johnson & Johnson, Bristol-Myers Canada and Helene Curtis Canada.

 

A description of the compensation payable to Mr. Wallace for his service as a director is set forth in the Company’s definitive Proxy Statement dated October 5, 2007, filed with the Securities and Exchange Commission on October 5, 2007, under the caption “Director Compensation,” and is incorporated herein by reference.

 

(e)  Not applicable.

 

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

 

(d): The following exhibit is being furnished herewith:

 

Exhibit No.		Exhibit
99.1		Press Release of ImmunoGen, Inc. dated November 19, 2007

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	ImmunoGen, Inc.
	(Registrant)
Date: November 19, 2007	/s/ Daniel M. Junius
	Daniel M. Junius
	Executive Vice President and Chief Financial Officer

 

 

3

 

128 Sidney Street, Cambridge, MA 02139-4239                           TEL: (617) 995-2500   FAX: (617) 995-2510

 

Contacts:

Investors		Media:
Carol Hausner		Kathryn Morris
Executive Director, Investor Relations and		KMorrisPR
Corporate Communications		(845) 635-9828
Tel: (617) 995-2500		Kathryn@kmorrispr.com
info@immunogen.com

 

For Immediate Release

ImmunoGen, Inc. Announces Addition of Richard Wallace to its Board of Directors

CAMBRIDGE, MA, November 19, 2007 — ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced the addition of Mr. Richard Wallace to the Company’s Board of Directors. Mr. Wallace has more than thirty years of experience in strategic product development and commercialization gained at leading healthcare companies and is currently a Senior Vice President of Research and Development at GlaxoSmithKline.

 

 

“Richard brings to our Board extensive expertise in the strategic development and commercialization of healthcare products, including experience in clinical development, health outcomes research, and the marketing of oncology products. We look forward to his contributions with the advancement of a number of our proprietary and partnered anticancer compounds toward registration trials and the marketplace,” commented Mitchel Sayare, Chairman and CEO.

 

Over his fifteen-year career at GlaxoSmithKline and its predecessors, Glaxo Wellcome and Glaxo, Mr. Wallace has held positions of increasing responsibility including Vice President, Sales and Marketing for oncology products at Glaxo Wellcome, Vice President, Therapeutic Development and Product Strategy at Glaxo Wellcome, and Vice President, Clinical Development and Product Strategy at GlaxoSmithKline. Before joining Glaxo Canada in 1992, Mr. Wallace held commercialization and/or strategic development-related positions with Unilever, Johnson & Johnson, Bristol-Myers Canada and Helene Curtis Canada.

 

About ImmunoGen, Inc.

 

ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company’s proprietary TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing — huN901-DM1 and huC242-DM4. Three TAP compounds are in clinical testing through ImmunoGen’s collaborations — AVE9633 and SAR3419, in development by sanofi-aventis, and trastuzumab-DM1 (T-DM1), in

 

 

 

development by Genentech. Additionally, the naked antibody compound, AVE1642, is in development through the Company’s collaboration with sanofi-aventis. Multiple compounds are in research/preclinical development through the ImmunoGen’s collaborations and internal programs.

 

# # #

 

 

2